Floatz logo

Epirubicin

Extrahepatic Bile Duct Cancer

University of NebraskaPhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Extrahepatic Bile Duct Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Lisata Therapeutics, Inc.
Phase 3BBB
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Capecitabine
National Cancer Institute (NCI)
Phase 3BB
Irinotecan
AIO-Studien-gGmbH
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Lisata Therapeutics, Inc.
Phase 2BB

View all 47 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →